Navigation Links
Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging
Date:10/29/2010

king it available in 30 countries across Europe. - Shire has seen rapid adoption of VPRIV worldwide. There are currently over 1,000 Gaucher patients treated with VPRIV and initiation of treatment continues. Based on its current manufacturing capacity, Shire anticipates being able to accommodate approximately 200 additional Gaucher patients until the approval of the Lexington Manufacturing facility provides substantial additional capacity. Shire has an ongoing program to monitor demand and manage requests for VPRIV. Shire's priority is ensuring long-term, uninterrupted treatment of patients on therapy. FIRAZYR - for the treatment of HAE - In October 2010, Shire submitted data to support a change in the label in the EU to include the potential for self-administered subcutaneous injections of FIRAZYR in patients who are experiencing acute attacks of HAE.

Pipeline

This quarter we have made significant developments in our pipeline, including:

Collaboration with Acceleron for ActRIIB molecules - On September 9, 2010 Shire announced the expansion of its HGT pipeline through the exclusive licence, in markets outside of North America, for the ActRIIB class of molecules being developed by Acceleron. The collaboration will initially investigate ACE-031, Acceleron's lead ActRIIB drug candidate, which is currently in a Phase 2a trial for the treatment of patients with Duchenne Muscular Dystrophy. ACE-031 and other ActRIIB molecules have the potential to be used in other muscular and neuromuscular disorders with high unmet medical need. Pipeline obtained through Movetis acquisition - The acquisition of Movetis brings to Shire a promising GI pipeline, offering additional opportunities that include two projects in early clinical development and several pre-clinical leads as well as the rights to a large library of qualified lead compounds with potential for development in different GI indications. VYVANSE for the adjunctive therapy in the treatment of ina
'/>"/>

SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Shire Announces Results of the Tender Offer for Movetis NV and Commencement of Squeeze-Out Tender Period
2. Reportlinker Adds Shire plc: PharmaVitae Profile
3. Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease
4. Shire plc - Statement re ProAmatine
5. Shire Proposes to Expand Specialist Gastrointestinal Portfolio
6. Lialda(R) - Shire Files Suit Against Cadila Healthcare Limited, Doing Business as Zydus Cadila and Zydus Pharmaceuticals (USA), Inc.
7. Shire Receives CHMP Positive Opinion for VPRIV(TM) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease in the European Union
8. Shire plc Appoints Two New Board Directors
9. INTUNIV(TM) - Shire Files Suit Against Anchen Pharmaceuticals, Inc. and Anchen, Inc.
10. Shire Receives 2010 Corporate Award From the National Organization for Rare Disorders (NORD) for the Development of VPRIV (velaglucerase alfa for Injection)
11. INTUNIV(TM) - Shire Files Suit Against Actavis Elizabeth LLC and Actavis Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... 27, 2015 Earlier this year, the ... of hair regrowth in adult men and women with ... Norwood Hamilton classifications of IIa-V and Fitzpatrick Classification of ... by products that over-promise and under-deliver, FDA Clearance underscores ... and confidence among more than 80 million men and ...
(Date:3/27/2015)... UK (PRWEB) March 27, 2015 The ... the back of the recession and high prices in ... market has recovered and keeps on gaining momentum now. ... NPK stands at more than 100,000 thousand tonnes. No ... years. Meantime, the global capacity rocketed during 2012-2013, registering ...
(Date:3/27/2015)... 2015  Peter Walter wurde als Gewinner ... seine bahnbrechende Arbeit ausgewählt, die sich damit ... sowie für die Entschlüsselung der Komponenten eines ... nutzen, der mit der Ansammlung von deformierten ... Biochemie an der University of California, San ...
(Date:3/27/2015)... 2015  Neogen Corporation (NASDAQ: NEOG ) announced ... trading plan in accordance with Securities and Exchange Commission ... of Neogen Corporation, is a minority owner of this ... Herbert does not have control of this ... is only for a portion of the shares owned ...
Breaking Biology Technology:Dr. Robert Leonard Applauds FDA Clearance of Capillus272Pro™ Hair Loss Laser Cap 2World NPK Fertilizers Market Keeps On Gaining Momentum, According to BAC Reports Study Available at MarketPublishers.com 2World NPK Fertilizers Market Keeps On Gaining Momentum, According to BAC Reports Study Available at MarketPublishers.com 3Deutschstämmiger Zellbiologe Peter Walter gewinnt den Vilcek Prize in Biomedical Science 2015 2Deutschstämmiger Zellbiologe Peter Walter gewinnt den Vilcek Prize in Biomedical Science 2015 3Deutschstämmiger Zellbiologe Peter Walter gewinnt den Vilcek Prize in Biomedical Science 2015 4Neogen CEO adopts 10b5-1 Trading Plan 2
... March 23, 2011 Tengion, Inc. (Nasdaq: ... the addition of two renal research and clinical experts, ... from the Harvard Stem Cell Institute and ... & Development Advisors. This panel provides counsel to Tengion ...
... nanotubes dipped in a polymer solution equal the energy output ... of Case Western Reserve University engineers has found. The ... power output and maintain the other advantages by matching the ... they,ve proved the simple technique can knock down one of ...
... Spherix Incorporated (Nasdaq: SPEX), ... diabetes, metabolic syndrome and atherosclerosis; and providers of ... biotechnology and pharmaceutical companies, today announced that its ... the BIO-Windhover/Pharmaceutical Strategic Outlook 2011 Conference to be ...
Cached Biology Technology:Tengion Announces Addition of Two Renal Experts to Research & Development Advisors Panel 2Tengion Announces Addition of Two Renal Experts to Research & Development Advisors Panel 3Tengion Announces Addition of Two Renal Experts to Research & Development Advisors Panel 4Tengion Announces Addition of Two Renal Experts to Research & Development Advisors Panel 5Cheap catalyst made easy 2Spherix to Present at the BIO-Windhover/Pharmaceutical Strategic Outlook 2011 Conference 2Spherix to Present at the BIO-Windhover/Pharmaceutical Strategic Outlook 2011 Conference 3
(Date:3/23/2015)... NEW YORK , March 23, 2015   ... digital property management company, today announced that the Company ... platform for both enterprise and consumers at Connect:ID on ... D.C. HOYOS Labs will highlight the IEEE ... 1U TM ; and enterprise access control system. ...
(Date:3/20/2015)... , Mar. 20, 2015 Research and Markets ... addition of the "India Sensors Market Forecast ... The sensor market is projected to ... Consumer electronics, automotive, industrial and healthcare ... in the country. In addition, adoption of MEMS ...
(Date:3/20/2015)... , Mar. 19, 2015 Research and Markets ... "Iris Biometrics - Global Strategic Business Report" report to ... for Iris Biometrics in US$ Thousands. The report provides separate ... Japan , Europe , ... , and Latin America . ...
Breaking Biology News(10 mins):HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 2India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5
... biomedical and health informatics, sent comments to the federal ... (DHHS/ ONCHIT), which has actively supported and incentivized the ... over the last year, and which solicited comment, through ... support for achieving meaningful use of EHRs in 2013 ...
... A new non-surgical post-mortem technique that has the ... the world has been pioneered by forensic pathologists and ... the University Hospitals of Leicester NHS Trust. The ... Forensic Pathology Unit, at the University of Leicester, has ...
... how farmers could protect themselves by growing a greater ... BioScience , has highlighted economical steps that farmers ... global climate change, including a greater frequency of extreme ... a policy priority for agriculture. The survey, by Brenda ...
Cached Biology News:AMIA on meaningful use: Invest in people and technology 2New non-surgical autopsy technique set to revolutionize post-mortem practice 2
... PrecisION Ion Channel Cell Lines ,High Quality, ... channels are well known for having a ... and consequently have a key function in ... modulate ion channels have been investigated in ...
Mouse monoclonal antibody raised against a partial recombinant ENTPD5. NCBI Entrez Gene ID = ENTPD5...
... Mouse monoclonal antibody raised ... Immunogen: ... 206 a.a) partial recombinant protein ... Accession Number: NM_005802 ...
Mouse monoclonal antibody raised against a partial recombinant IL31RA. NCBI Entrez Gene ID = IL31RA...
Biology Products: